<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347638">
  <stage>Registered</stage>
  <submitdate>26/10/2011</submitdate>
  <approvaldate>2/11/2011</approvaldate>
  <actrnumber>ACTRN12611001150932</actrnumber>
  <trial_identification>
    <studytitle>Dyslipidaemia, Oxidative Stress And Arterial Wall Function In Non-Insulin Dependent Diabetes</studytitle>
    <scientifictitle>A Double-Blind Randomised Placebo-Controlled Trial Of The Effects Of Fenofibrate And Coenzyme Q10 On Arterial Function In Type 2 Diabetic Subjects With Dyslipidaemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NHMRC Grant Project Number: 970154</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Dyslipidaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1.Fenofibrate 200mg/day orally
2.Coenzyme Q10 200mg/day orally
3.Fenofibrate 200mg/day plus Coezyme Q10 200mg/day orally
4.Placebo
All for 12 weeks</interventions>
    <comparator>Placebo, microcellulose</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acetylcholine-stimulated forearm blood flow measured by strain gauge plethysmography</outcome>
      <timepoint>At baseline (week 0) and at week 12 after treatment randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperaemic response in forearm blood flow following venous occlusion measured by strain gauge plethysmography</outcome>
      <timepoint>At baseline (week 0) and at weeks 6 and 12 after treatment randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperaemic flow-mediated dilatation of the brachial artery following arterial occlusion measured by ultrasonography</outcome>
      <timepoint>At baseline (week 0) and at weeks 6 and 12 after treatment randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes 

Dyslipidaemia (fasting serum triglycaeride &gt;1.8mmol/L or HDL-cholesterol &lt;1.0mmol/L, with total cholesterol &lt;6.5mmol/L and total cholesterol-to-HDL-cholesterol ratio &gt;4)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Use of antioxidant or lipid-regulating therapy, insulin, angiotensin-converting enzyme inhibitors, calcium antagonists or aspirin

Body mass index &gt;40kg/m2

Uncontrolled hypertension (&gt;160/90mmHg)

Serum creatinine &gt;150umol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/1997</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Gerald F Watts</primarysponsorname>
    <primarysponsoraddress>University of Western Australia
School of Medicine and Pharmacology
Royal Perth Hospital Unit
GPO Box X2213
Perth WA 6847</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess whether the combination of fenofibrate and coenzyme Q improves vascualr health in diabetes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>GPO Box X2213
Perth WA 6847</ethicaddress>
      <ethicapprovaldate>12/12/1996</ethicapprovaldate>
      <hrec>EC460</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Gerald F Watts</name>
      <address>University of Western Australia
School of Medicine and Pharmacology
Royal Perth Hospital Unit
GPO Box X2213
Perth WA 6847</address>
      <phone>+61802240245</phone>
      <fax>+61802240246</fax>
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Gerald F Watts</name>
      <address>University of Western Australia
School of Medicine and Pharmacology
Royal Perth Hospital Unit
GPO Box X2213
Perth WA 6847</address>
      <phone>+61802240245</phone>
      <fax>+61802240246</fax>
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Gerald F Watts</name>
      <address>University of Western Australia
School of Medicine and Pharmacology
Royal Perth Hospital Unit
GPO Box X2213
Perth WA 6847</address>
      <phone>+61802240245</phone>
      <fax>+61802240246</fax>
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>